摘要
目的:本文旨在介绍芳香化酶抑制剂进展的侧面。方法:采用国内、外文献综述方法。结果与结论:芳香化酶抑制剂进展十分迅速,其对酶的选择性高,用于绝经后晚期乳腺癌和早期乳癌术后辅助治疗的地位已经确立。新一代芳香化酶抑制剂与早期的抑制剂相比,其疗效和酶抑制作用均有显著差异,与其优异的疗效有一致性,使乳癌的治疗不再棘手,在姑息治疗上展现了良好的前景。
OBJECTIVE： To summarize the aspect of clinical application and progress on aromatase inhibitor. METHODS：To collecte medical literatures in recent years at home and abroad. RESULTS ＆ CONCLUSION：Advance in synthetise of the aromatase inhibitor（AI）has been swiftly in rencent years, with higher selectivity to aromatase. Position for the treatment of late breast cancer and postoperative adjuvant treatment of early breast cancer is made certain. The new aromatase inhibitor have more advantages compared with early ones, the founding of aromatase inhibitor makes treatment of breast cancer easier. It plays an important roles in palliative treatment patients with breast cancer.
出处
《中国医院用药评价与分析》
2005年第4期205-207,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
芳香化酶抑制剂
乳腺肿瘤
姑息治疗
应用
aromatase inhibitor
breast cancer
palliative treatment
application
